OIE Reference Laboratory Reports Activities

Size: px

Start display at page:

Download "OIE Reference Laboratory Reports Activities"

Ethel Ellis
5 years ago
Views:

1 OIE Reference Laboratory Reports Activities Activities in 2016 This report has been submitted : :05:00 Name of disease (or topic) for which you are a designated OIE Reference Laboratory: Newcastle disease Address of laboratory: Südufer 10 D Greifswald Insel Riems GERMANY Tel.: / 1 Fax: address: christian.grund@fli.de Website: Name (including Title) of Head of Laboratory (Responsible Official): Dr. Christian Grund Name (including Title and Position) of OIE Reference Expert: Dr. Christian Grund Which of the following defines your laboratory? Check all that apply: Governmental OIE Reference Laboratory Reports Activities,

2 ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards 1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (t for quality control, proficiency testing or staff training) Diagnostic Test Indicated in OIE Manual (/) Total number of test performed last year Indirect diagnostic tests Nationally Internationally Heamagglutination inhibition test yes 256 / Direct diagnostic tests Nationally Internationally virus isolation yes RT-qPCR (M-,NP,F-gene) no RTPCR (F-gene) yes Nucleotide sequencing yes intracerebral pathogenicity index (ICPI) yes 6 13 ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease. 2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE? 3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries? 4. Did your laboratory produce vaccines? 2 OIE Reference Laboratory Reports Activities, 2016

3 5. Did your laboratory supply vaccines to OIE Member Countries? ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases 6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease? 7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease? Name of the new test or diagnostic method or vaccine developed F-gene specific RT-qPCR for Genotype VII viruses from Egypt (F-EGY- RT-qPCR) Description and References (Publication, website, etc.) 22nd Annual Meeting of EU AI/ND reference laboratories. Manuscript in preparation ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries 8. Did your laboratory carry out diagnostic testing for other OIE Member Countries? Name of OIE Member Country seeking assistance Date (month). samples received for provision of diagnostic support. samples received for provision of confirmatory diagnoses EGYPT Jan-Aug 0 47 PERU Feb Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country? Name of the OIE Member Country receiving a technical consultancy Purpose How the advice was provided ISRAEL Evaluation of efficacy of current ND-vaccination round table discussion with stake holders, final report OIE Reference Laboratory Reports Activities,

4 ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations 10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own? ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases 11. Did your Laboratory collect epizootiological data relevant to international disease control? 12. Did your laboratory disseminate epizootiological data that had been processed and analysed? 13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category) a) Articles published in peer-reviewed journals: 7 1: Adlhoch C, Brown IH, Angelova SG, Bálint Á, Bouwstra R, Buda S, Castrucci MR, Dabrera G, Dán Á, Grund C, Harder T, van der Hoek W, Krisztalovics K, Parry-Ford F, Popescu R, Wallensten A, Zdravkova A, Zohari S, Tsolova S, Penttinen P. Highly pathogenic avian influenza A(H5N8) outbreaks: protection and management of exposed people in Europe, 2014/15 and Euro Surveill Dec 8;21(49). pii: doi: / ES PubMed PMID: ; PubMed Central PMCID: PMC : Abdelwhab EM, Veits J, Tauscher K, Ziller M, Grund C, Hassan MK, Shaheen M, Harder TC, Teifke J, Stech J, Mettenleiter TC. Progressive glycosylation of the haemagglutinin of avian influenza H5N1 modulates virus replication, virulence and chicken-to-chicken transmission without significant impact on antigenic drift. J Gen Virol Dec;97(12): doi: /jgv PubMed PMID: : Globig A, Starick E, Homeier T, Pohlmann A, Grund C, Wolf P, Zimmermann A, Wolf C, Heim D, Schlößer H, Zander S, Beer M, Conraths FJ, Harder TC. Epidemiological and Molecular Analysis of an Outbreak of Highly Pathogenic Avian Influenza H5N8 clade in a German Zoo: Effective Disease Control with Minimal Culling. Transbound Emerg Dis v 15. doi: /tbed [Epub ahead of print] PubMed PMID: : Oliveira Cavalcanti M, Vaughn E, Capua I, Cattoli G, Terregino C, Harder T, Grund C, Vega C, Robles F, Franco J, Darji A, Arafa AS, Mundt E. A genetically engineered H5 protein expressed in insect cells confers protection against different clades of H5N1 highly pathogenic avian influenza viruses in chickens. Avian Pathol Jan 27:1-10. doi: / [Epub ahead 4 OIE Reference Laboratory Reports Activities, 2016

5 of print] PubMed PMID: Newcastle disease - Christian Grund - germany 5: Poen MJ, Verhagen JH, Manvell RJ, Brown I, Bestebroer TM, van der Vliet S, Vuong O, Scheuer RD, van der Jeugd HP, let BA, Kleyheeg E, Müskens GJ, Majoor FA, Grund C, Fouchier RA. Lack of virological and serological evidence for continued circulation of highly pathogenic avian influenza H5N8 virus in wild birds in the Netherlands, 14 vember 2014 to 31 January Euro Surveill Sep 22;21(38). doi: / ES PubMed PMID: ; PubMed Central PMCID: PMC : Abdelwhab EM, Grund C, Aly MM, Beer M, Harder TC, Hafez HM. Benefits and Limits of Egg Yolk vs. Serum Samples for Avian Influenza Virus Serosurveillance. Avian Dis Jun;60(2): doi: / Reste. PubMed PMID: : Abdelwhab EM, Hassan MK, Abdel-Moneim AS, Naguib MM, Mostafa A, Hussein IT, Arafa A, Erfan AM, Kilany WH, Agour MG, El-Kanawati Z, Hussein HA, Selim AA, Kholousy S, El-Naggar H, El-Zoghby EF, Samy A, Iqbal M, Eid A, Ibraheem EM, Pleschka S, Veits J, Nasef SA, Beer M, Mettenleiter TC, Grund C, Ali MM, Harder TC, Hafez HM. Introduction and enzootic of A/H5N1 in Egypt: Virus evolution, pathogenicity and vaccine efficacy ten years on. Infect Genet Evol Jun;40: doi: /j.meegid Review. PubMed PMID: b) International conferences: 3 1.) Grund C.. (2016) Navigation to Diagnose NDV:comparison of methods. 22nd EU AI/ND NRL Meeting, Copenhagen ; 2.) Grund C, Schwarz M, Schwefer S, Desloges N. (2016) Time as critical Parameter of turkeys against Newcastle disease. (2016) International Symposium on Turkey Diseases. Berlin ; 3.) Grund C, Harder T, Beer M. (2016) Choosing the right platform when developing a new vaccine for an emerging disease: World Vet Vaccine Congress. Barcelona c) National conferences: 2 1.) Grund C, Harder T, Hoffmann B, Conraths F und Beer M. (2016) Aktuelles zur Avären Influenza. Leipziger Tierärzte Kongress. Leipzig, ; 2.) Grund C. (2016) Immer Ärger mit dem Taubentyp: Newcastle Krankheit aus deutscher und internationaler Perspektive. Diagnostik und Betreuung von Wirtschafts- und ziergeflügel. Stendal ; d) Other: (Provide website address or link to appropriate information) 0 ToR 7: To provide scientific and technical training for personnel from OIE Member Countries To recommend the prescribed and alternative tests or vaccines as OIE Standards 14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries? a) Technical visits: 1 OIE Reference Laboratory Reports Activities,

6 b) Seminars: 0 c) Hands-on training courses: 1 d) Internships (>1 month): 0 Type of technical training provided (a, b, c or d) Country of origin of the expert(s) provided with training. participants from the corresponding country a Israel 25 c Egypt 1 ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned 15. Does your laboratory have a Quality Management System certified according to an International Standard? Quality management system adopted ISO 17025:2005 Certificate scan (PDF, JPG, PNG format) Akkreditierung_2015.pdf 16. Is your laboratory accredited by an international accreditation body? Test for which your laboratory is accredited Heamagglutination inhibition assay amplification assays bio assys Accreditation body DAKKS; DAKKS is a member of the European cooperation for DAKKS DAKKS 17. Does your laboratory maintain a biorisk management system for the pathogen and the disease concerned? (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4) ToR 9: To organise and participate in scientific meetings on behalf of the OIE 18. Did your laboratory organise scientific meetings on behalf of the OIE? 6 OIE Reference Laboratory Reports Activities, 2016

7 19. Did your laboratory participate in scientific meetings on behalf of the OIE? ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results 20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease? 21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests? 22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest? Title of the project or contract Scope Name(s) of relevant OIE Reference Laboratories OIE Terrestrial Manual: Chapter on Newcastle disease revise manual APHA, CAHEC, APHIS ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results 23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease? te: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: see point 1.3 OIE Reference Laboratory Reports Activities,

8 Purpose for inter-laboratory test comparisons 1. participating laboratories Region(s) of participating OIE Member Countries NDP Pathotyping 29 Africa Americas Asia and Pacific Europe Middle East NDV Antibody testing Africa Americas Asia and Pacific Europe Middle East ToR 12: To place expert consultants at the disposal of the OIE 24. Did your laboratory place expert consultants at the disposal of the OIE? Kind of consultancy Location Subject (facultative) expert Mission to the country Israel Evaluation of NDV vaccination efficacy 25. Additional comments regarding your report: 8 OIE Reference Laboratory Reports Activities, 2016

OIE Reference Laboratory Reports Activities

OIE Reference Laboratory Reports Activities Activities in 2016 This report has been submitted : 2017-01-31 14:46:00 Name of disease (or topic) for which you are a designated OIE Reference Laboratory: Newcastle